The Current Ratio as of October 2024 (TTM) for Protagonist Therapeutics, Inc. (PTGX) is 13.73

According to Protagonist Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 13.73. This represents a change of -5.02% compared to the average of 14.46 of the last 4 quarters.

Protagonist Therapeutics, Inc. (PTGX) Historical Current Ratio (quarterly & annually)

How has PTGX Current Ratio performed in the past?

The mean historical Current Ratio of Protagonist Therapeutics, Inc. over the last ten years is 7.76. The current 13.73 Current Ratio has changed 17.59% with respect to the historical average. Over the past ten years (40 quarters), PTGX's Current Ratio was at its highest in in the September 2016 quarter at 19.11. The Current Ratio was at its lowest in in the March 2015 quarter at 0.

Protagonist Therapeutics, Inc. (PTGX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Protagonist Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Protagonist Therapeutics, Inc. (PTGX) Average Current Ratio

How has PTGX Current Ratio performed in the past?

The current Current Ratio of Protagonist Therapeutics, Inc. (PTGX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Protagonist Therapeutics, Inc. (PTGX) Current Ratio vs. Peers

How is PTGX’s Current Ratio compared to its peers?

Protagonist Therapeutics, Inc.’s Current Ratio is less than Revolution Medicines, Inc. (15.42), less than Akero Therapeutics, Inc. (24.89), less than Avidity Biosciences, Inc. (15.78), greater than Stoke Therapeutics, Inc. (6.67), less than Kura Oncology, Inc. (14.94), greater than Merus N.V. (9.97), greater than Replimune Group, Inc. (13.46), greater than Cerevel Therapeutics Holdings, Inc. (10.22), less than Relay Therapeutics, Inc. (15.64), less than Pliant Therapeutics, Inc. (14.47), greater than Black Diamond Therapeutics, Inc. (6.87), greater than Arvinas, Inc. (3.62), less than Ventyx Biosciences, Inc. (14.19), less than IDEAYA Biosciences, Inc. (17.50), greater than Verona Pharma plc (8.61), greater than Syndax Pharmaceuticals, Inc. (10.50), less than Terns Pharmaceuticals, Inc. (21.02), greater than X4 Pharmaceuticals, Inc. (6.07), less than Acumen Pharmaceuticals, Inc. (17.37), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than HOOKIPA Pharma Inc. (3.86),

Build a custom stock screener for Protagonist Therapeutics, Inc. (PTGX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protagonist Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Protagonist Therapeutics, Inc. (PTGX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Protagonist Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.